Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Preclinical data shines: >85% tumor growth inhibition in pancreatic models, reduced fibrosis and resistance markers, and a gentler safety profile
March 03, 2026 02:30 ET | Source: Montis Biosciences

Montis Biosciences Advances First-in-Class Dual-Action C1q Antibody with Strong Preclinical Proof-of-Concept in Neuroinflammatory Diseases

Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated...
March 02, 2026 16:00 ET | Source: Cytokinetics, Incorporated

Cytokinetics to Participate in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the...
March 02, 2026 07:55 ET | Source: UroGen Pharma Ltd.

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors

Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded at closing to refinance the existing $125...
March 01, 2026 21:03 ET | Source: InnoCare Pharma

InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China

InnoCare’s next-generation TRK inhibitor Zurletrectinib receives priority review for the treatment of pediatric patients with solid tumors in China.
February 27, 2026 08:00 ET | Source: ALX Oncology

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

ALX Oncology Q4 and EOY 2025 earnings press release
February 27, 2026 07:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a...
February 26, 2026 12:03 ET | Source: Society For Science

Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders

Regeneron is renewing it's sponsorship of the Science Talent Search for the next 10 years, committing $150 million.
February 26, 2026 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome

NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome
February 26, 2026 08:00 ET | Source: Cannara Biotech (Québec) Inc.

Cannara annonce son entrée à la Bourse de Toronto

MONTRÉAL, 26 févr. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la «Société », « nous » ou « notre ») (TSXV : LOVE) (OTCQX : LOVFF) (FRA : 8CB0), producteur verticalement...